Clinical Trial Update: Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Nimotuzumab with Paclitaxel and Cisplatin for metastatic esophageal squamous cell carcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Nimotuzumab (nimotuzumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Biotech Pharmaceutical Co., Ltd. | Conditions: Esophageal Squamous Cell Carcinomas | Phase 3 | Status: UNKNOWN